viewScancell Holdings PLC

Scancell says it is working closely with US regulators ahead of phase II study of cancer immunotherapy

The UK group is planning to use its SCIB1 in harness with Merck’s Keytruda to treat patients with advanced melanoma

woman researcher working in lab
The company hopes the study will get underway in the first half of next year

Scancell Holdings Plc (LON:SCLP) said it is working closely with the US drugs regulator to address questions raised ahead of the launch of a phase II clinical study of its cancer immunotherapy.a

The UK group is planning to use its SCIB1 in harness with Merck’s Keytruda to treat patients with advanced melanoma.

Ahead of granting investigational new drug status, America’s Food & Drug Administration has requested some additional information.

Focus on TriGrid

The queries are focused on a technology called TriGrid, a delivery system developed by Ichor Medical Systems that is also part of the combination therapy.

Chief executive Cliff Holloway said: "We are working closely with Ichor and the FDA to address the questions they have raised and we are confident we can respond to these in a timely manner. 

“We continue to advance the operational processes and procedures to ensure a rapid start to the study once approval is obtained."

Subject to regulatory sign-off, Scancell expects patient enrolment to begin in the first half of next year.

Quick facts: Scancell Holdings PLC

Price: 21 GBX

Market: LSE
Market Cap: £171.2 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Scancell Holdings PLC named herein, including the promotion by the Company of Scancell Holdings PLC in any Content on the Site, the Company...


Scancell Holdings highlights 'most transformative period Scancell has ever...

Scancell Holdings PLC's (LON:SCLP) Cliff Holloway talks to Proactive London about the six month period ending ended October 31, 2020, described by Holloway as the 'most transformative period Scancell has ever experienced'. He highlights their strengthened cash position, 'which has allowed us...

on 1/2/21

2 min read